Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We do believe, without specifically answering your question, that we have considerable optionality here just based on the nature of the disease, the very limited treatment options and what we believe is a very favorable product profile, as I described, both from an activity perspective as well as AE profile |
| And again, I truly believe that we will be positioned very well from a duration standpoint and mechanistically to -- against bleeding signal that was detected with BTKi's |
| And as Jim stated, we are very encouraged with our accumulating data of Iopofosine activity in multiple myeloma, multiple subset patients, including triple, quadruple, penta-refractory and those with post-BCMA relapse of the disease |
| We are confident that novel mechanisms of action and the advantages of short duration of therapy, as mentioned for WM, will also be a benefit for patients with WM |
| We view this designation as a significant achievement |
| And we believe that we are certainly well positioned in comparison to, as you mentioned, BTKi's in terms of specifically bleeding hematologic profile for a couple of reasons |
| And there's a level of high commitment to help expedite or accelerate products like this that they deem solve an unmet clinical need or an underserved population and that the drug itself provides a meaningful improvement over existing agents |
| We are hearing from our KOLs in multiple myeloma field that we do have clear and significant advantages, again, based on MOA, depth to responses we see, especially in very highly refractory patients |
| Based on our assessments, we believe there is a significant opportunity for Iopofosine to improve and expand treatment in a substantial concentrated, prevalent patient population by potentially providing improved major response rates and complete responses with a fixed dosing schedule versus continuous therapy |
| Additional survey information received from WM treaters highlights the significant opportunity for new treatment options with improved efficacy |
| Based on our ongoing evaluation of the WM market and customer feedback on Iopofosine's potential profile, we remain optimistic that Iopofosine may play a meaningful role in the treatment of WM and in patient quality of life |
| Importantly, third-party market sizing research commissioned by Cellectar suggests a strong market opportunity with a third line or greater addressable population of approximately 4,300 patients |
| In summary, we have made excellent progress with our WM market assessments and associated commercial planning while optimizing resource allocation |
| They're very encouraged with coming -- to their patients with novel MOA after all available treatment options are exhausted |
| I think it was a very good decision |
| We believe we have some considerable optionality here |
| You have likely seen the results from our Phase IIa clinical study, which are impressive and served as a basis for further evaluation of Iopofosine I-131 in Waldenstrom macroglobulinemia |
| So first, we recently published results in few patients right after previous ASH on both BCMA-treated patients with very encouraging results in terms of response and duration of response for this population |
| So those cytopenias, which are very manageable and both lymphoma and hematologists experts will tell you very comfortable in terms of the management of that, you have a really nice product profile |
| On the financial front, we recently completed a successful PIPE led by Rosalind Advisors with participation from an excellent group of new and existing institutional investors, including AIGH Capital, ADAR1, Second Line, Nantahala Capital and AuGC, among others |
| Importantly, the duration of response was clinically meaningful beyond 20 months and compares favorably to all available options in this population |
| This indicates that these patients have exhausted the limited FDA-approved therapies and experienced disease progression or treatment toxicity, which means there are no proven options and only salvage therapies available for next line of treatment, creating a rapidly available market expansion opportunity |
| We further strengthened our global intellectual property portfolio with the addition of 4 new patents and secured PRIME designation in Europe for Iopofosine in relapsed/refractory WM |
| And that excitement certainly is very visible and encourages us to continue our development |
| For the reasons previously described, WM represents a significant commercial opportunity, including the sizable patient population, limited existing treatment options, orphan disease pricing and Iopofosine's novel product profile |
| These are accounts which have a high WM claims profile and they have radiotherapeutic capabilities |
| It is our belief that Iopofosine I-131 product profile will provide a novel and meaningful treatment option for patients suffering from WM |
| We believe Iopofosine's product profile will address these issues by providing a new targeted MOA and the potential for increased efficacy across all genotypes, including complete responses with meaningful progression-free survival |
| And so I think that's going to afford us the opportunity leveraging smart data to build out a very efficient go-to-market model, which would exist and continue poking the field across various functions, both medical sales liaisons, health care hematology specialists, we'd have standard -- normal marketing functions |
| We remain committed to supporting WM patients, and we'll continue to move forward with a strong sense of urgency and purpose |
| Statement |
|---|
| This likely represents the inability of BTKi drugs to achieve meaningful disease volume reduction |
| One, I will direct you to our receipt or we were awarded the PRIME designation, which, as you know, is very difficult especially over the last handful of years, more and more challenging to receive that from the EU |
| It is further characterized by uncontrolled production of IgM monoclonal protein, not dissimilar for multiple myeloma, that by itself presents risk of significant morbidity |
| And today's environment is, quite frankly, more challenging than breakthrough designation in the U.S |
| It's a challenge, Jonathan, for those patients |
| High treatment exposure to approved therapies, significant refractory disease, apathy resulting from limited FDA-approved options and the need for novel MOAs with improved efficacy were key issues cited by WM treaters |
| And so it is a difficult and challenging-to-treat population |
| Currently, treatment options are extremely limited beyond second-line therapy and they typically achieve poor major response rates with no complete responses reported |
| The challenge, as understandable that we are mitigating, is rapidly evolving field of multiple myeloma and optionality for patients with this disease and continuously added new treatments |
| Chemotherapy is not applicable to a significant proportion of patients due to development of resistance, poor tolerance and has a significant impact on quality of life of patients with this incurable malignancy |
| The difference in Europe is we do not obviously have the capacity to successfully promote there as a stand-alone |
| Following up on Jonathan's question around the confirmatory study, the agency has been making noises on occasion about having confirmatory studies agreed to or in some cases, even begun prior to accepting the NDA application or alternatively approving the product |
| It is characterized by slow indolent growth, but eventually the crowding of the bone marrow results in cytopenias and suppression of the immune system, raising the risk of infection |
| Jason Mccarthy And last question just briefly, just from a safety profile aspect along with that top line data, would you mention lack of bleeding risk? The bleeding became issues, obviously, with WM generally, but the BTKs, when that second one was developed, that became an area of investor focus |
| WM remains incurable despite currently available therapies |
| Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, actual outcomes and results are subject to risks and uncertainties that could differ materially from those forecast due to the impact of many factors beyond the control of Cellectar |
Please consider a small donation if you think this website provides you with relevant information